Publikationen in Zusammenarbeit mit Forschern von Maastricht University (76)

2025

  1. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses

    European Neuropsychopharmacology, Vol. 90, pp. 1-15

2024

  1. A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    Schizophrenia Research, Vol. 266, pp. 237-248

  2. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

  3. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study

    Psychiatry Research, Vol. 342

  4. Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    Schizophrenia, Vol. 10, Núm. 1

  5. PsyCog: A computerised mini battery for assessing cognition in psychosis

    Schizophrenia Research: Cognition, Vol. 37

  6. Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study

    Psychological medicine, Vol. 54, Núm. 8, pp. 1810-1823

2023

  1. Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

    Molecular Psychiatry, Vol. 28, Núm. 3, pp. 1201-1209

  2. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: Results from the EU-GEI case-control study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7375-7384

  3. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  4. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  5. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  6. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  7. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

  8. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data

    Schizophrenia bulletin, Vol. 49, Núm. 1, pp. 218-227

  9. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 14

  10. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

    Psychological medicine, Vol. 53, Núm. 15, pp. 7418-7427

  11. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  12. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

  13. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3396-3405